Athira Pharma (NASDAQ:ATHA) Shares Down 4.7% – Here’s What Happened
by Doug Wharley · The Cerbat GemShares of Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) dropped 4.7% during trading on Thursday . The stock traded as low as $9.17 and last traded at $9.62. Approximately 22,822 shares traded hands during trading, a decline of 96% from the average daily volume of 602,475 shares. The stock had previously closed at $10.09.
Athira Pharma Stock Performance
The stock has a market cap of $40.74 million, a PE ratio of -1.07 and a beta of 2.79. The company’s 50-day moving average price is $9.57 and its 200 day moving average price is $6.83.
Institutional Trading of Athira Pharma
Several institutional investors have recently made changes to their positions in the company. Focus Partners Wealth purchased a new stake in shares of Athira Pharma during the 3rd quarter valued at approximately $35,000. Jane Street Group LLC purchased a new stake in shares of Athira Pharma during the 4th quarter valued at approximately $100,000. Renaissance Technologies LLC raised its position in shares of Athira Pharma by 44.7% during the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock valued at $569,000 after buying an additional 23,223 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Athira Pharma during the 4th quarter valued at approximately $969,000. Finally, Millennium Management LLC purchased a new stake in shares of Athira Pharma during the 4th quarter valued at approximately $2,456,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.
About Athira Pharma
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.